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Abstract
Cytogenetically unrelated clones have been detected
by chromosome banding analysis in many breast
carcinomas. Because these karyotypic studies were
performed on short - term cultured samples, it may be
argued that in vitro selection occurred or that small
clones may have arisen during culturing. To address
this issue, we analyzed 37 breast carcinomas by G-
banding and comparative genomic hybridization
(CGH), a fluorescent in situ hybridization–based
screening technique that does not require culturing
or tumor metaphases. All but two of the 37 karyotypi-
cally abnormal cases presented copy number changes
by CGH. The picture of genomic alterations revealed
by the two techniques overlapped only partly. Some-
times the CGH analysis revealed genomic imbalances
that belonged to cell populations not picked up by the
cytogenetic analysis and in other cases, especially
when the karyotypes had many markers and chromo-
somes with additional material of unknown origin,
CGH gave a more reliable overall picture of the copy
number gains and losses. However, besides some-
times revealing cell populations with balanced chro-
mosome aberrations or unbalanced changes that
nevertheless remained undetected by CGH, G-banding
analysis was essential to understand how the genomic
imbalances arose in the many cases in which both
techniques detected the same clonal abnormalities.
Furthermore, because CGH pictures only imbalances
present in a significant proportion of the test sample,
the very detection by this technique of imbalances
belonging to apparently small, cytogenetically unre-
lated clones of cells proves that these clones must
have been present in vivo. This constitutes compelling
evidence that the cytogenetic polyclonality observed
after short - term culturing of breast carcinomas is not
an artifact. Neoplasia (2001) 3, 204–214.
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Introduction
Chromosome banding analysis of breast carcinomas has
demonstrated extensive clonal cell - to-cell variation in the
tumors [1,2]. Intriguingly, this intratumor cytogenetic hetero-
geneity takes the form of karyotypically unrelated clones in a
significant proportion of cases, approaching 70% in series
subjected to particularly detailed analysis [3,4 ]. Because the
karyotypic studies demonstrating cytogenetic polyclonality
were all performed after short - term culture of the tumor cells
and because different cell populations may have different
growth rates in vitro, the relative clonal sizes revealed by the
cytogenetic analysis does not necessarily correspond to the
in vivo situation. It can furthermore be argued that some of
the observed clonal changes, especially the ones detected in
only a small number of metaphases, may have arisen during
culturing.
Comparative genomic hybridization (CGH) is a fluo-
rescent in situ hybridization–based screening technique
that, in a quantitative manner, detects gains and losses
of genomic material [5,6]. Because CGH does not
require tumor metaphases and hence is independent of
the mitotic activity of clonal subpopulations, the techni-
que is free from selection biases. However, only
imbalances present in a significant proportion of the test
sample are revealed by CGH and hence intratumor
heterogeneity manifesting itself as minor clones will go
unnoticed. The simultaneous detection by CGH of
genomic imbalances pertaining to cytogenetically unre-
lated clones would therefore, regardless of how many
metaphase cells displayed the characteristic aberrations
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after in vitro culturing, provide compelling evidence that
each clone was large in vivo and, indirectly, that both or
all constituted significant parts of the tumor parenchyma.
Taking advantage of these disparate qualities of the two
techniques, we performed a combined G-banding and
CGH analysis of a series of breast carcinomas to obtain
more information on the nature of genetic polyclonality
in breast cancer.
Materials and Methods
Tumor Specimens
Thirty -seven breast carcinomas from patients admitted
to Odense University Hospital from 1992 to 1994 were
selected because they had been shown to carry clonal
chromosome abnormalities by chromosome banding
analysis and because frozen material for DNA extraction
was available. The samples for G-banding and CGH
analyses were obtained before any chemo- or radio-
therapy.
Histopathology
The histopathologic classification (Table 1), which
included examination of slides from tissue immediately
adjacent to that processed for genetic analysis, was made
in accordance with WHO recommendations [7]. The
carcinomas were ductal not otherwise specified (NOS, 17
cases), comedo (11 cases), papillary, cribriform (two cases
each), mucinous, lobular, mixed ductal and lobular, ductal
carcinoma in situ (DCIS), and ductal carcinoma with
extensive DCIS component (one case each). Histopatho-
logic grading was based on the three components tubular
formation, mitotic index, and nuclear pleomorphism, and
quantified to allow a correlation study with the complexity of
the genetic changes. Each component was scored from 1 to
3 (Table 1) with their sum corresponding to grade I (3 to 5),
grade II (6 or 7), or grade III (8 or 9). The scores 1 and 2 for
each of the three components, as well as grades I and II,
were grouped together for the purpose of statistical analysis
(Table 2).
Chromosome Banding Analysis
Cells were short - term cultured and analyzed cytoge-
netically as previously described [8]. Briefly, all samples
were mechanically and enzymatically disaggregated, and
the resulting cells were plated out in 25-cm2 Primaria
flasks or Vitrogen-coated slide- flasks. The cultures
were fed an appropriate medium that facilitates epithe-
lial growth and harvested after 5 to 8 days. The cells
were exposed to demecolcine, dislodged by trypsiniza-
tion, subjected to hypotonic shock in 0.05 M KCl, and
fixed in methanol:acetic acid (3:1). G-banding was
obtained with Wright stain. The clonality criteria and the
description of karyotypes followed the recommendations
of the ISCN (1995) [9 ]. The G-banding karyotypes of
7 of the 37 cases have been published before [10]
(cases 386/92, 503/92, 46/93, 467/93, 136/93, 361/
93, and 145/93); the remainder are described here for
the first time.
Comparative Genomic Hybridization
The CGH procedure of Kallioniemi et al. [6 ] was
performed with the modifications previously described in
detail by Kraggerud et al. [11]. Briefly, test ( tumor) and
reference (peripheral blood lymphocytes from a healthy
female) DNA was extracted using standard methods and
labeled in nick- translation reactions using two fluoro-
chrome-conjugated nucleotides in each (New England
Nuclear, Boston, MA; FITC-12-dCTP and FITC-12-dUTP
for tumor DNA and Texas Red-6-dCTP and Texas Red-6-
dUTP for normal DNA), after which DNA fragment lengths
between 300 and 2000 bp were obtained. The same
amounts of labeled tumor and reference DNA (800 ng each)
were mixed with 20 g unlabeled Cot-1 DNA (Life
Technologies, Rockville, MD), ethanol -precipitated, dried
and dissolved in hybridization buffer (Vysis, Downers Grove,
IL). Normal metaphases were obtained by lymphocyte
culture from healthy donors or, in six cases, from commer-
cially available slides (Vysis). After denaturing the chromo-
somes and the DNA probe, hybridization was allowed to
occur for 2 to 3 days in a humidified chamber at 378C. After a
series of washes, the slides were mounted in an antifade
solution with DAPI (Vectashield; Vector Laboratories,
Burlingame, CA).
Ten good-quality metaphase spreads were selected for
analysis in each case. Three images, corresponding to FITC
(green) and Texas Red (red) hybridization signals and DAPI
counterstain, were sequentially captured with a Cohu 4900
CCD (12-bit gray scale) camera, using an automated filter
wheel coupled to a Zeiss Axioplan fluorescence microscope
(Zeiss, Oberkochen, Germany), and a CytoVision system
(Applied Imaging, Santa Clara, CA). Chromosomes were
identified based on their inverted DAPI appearance and the
relative hybridization signal intensity determined along each
chromosome. Data obtained from the 10 cells were
combined to generate average ratio profiles with 95%
confidence intervals for each chromosome. The threshold
values 1.25 and 0.75 were used to score gain and loss of
DNA sequences, respectively, corresponding to the ability of
detecting one copy number change in at least 50% of the
cells in a diploid tumor. Scoring was performed independ-
ently by two of the authors (M.R.T. and R.A.L. ) with few
interobserver differences; these were resolved after joint
reevaluation. A negative (normal versus normal ) and a
positive ( the cell line LOVO with known copy number
changes) control were included in every set of experiments.
Furthermore, the findings were controlled by repeated,
independent analyses of 16 tumors, including the use of
reverse labeling in four tumors. The description of the CGH
copy number changes followed the guidelines suggested in
the ISCN (1995) [9 ].
Evaluation of Genetic Complexity
The karyotypic complexity, i.e., the number of cytogenetic
abnormalities detected by chromosome banding analysis,
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was determined by counting the aberrations described in the
karyotype in each case according to the following criteria:
Multiple copies of structural or numerical abnormalities were
counted only once; in derivative chromosomes, each
structural change was counted, and each individual marker
was counted once. The number of changes detected by CGH
was arrived at by adding the number of copy number gains
and losses indicated in Table 1. Because the average
Table 1. Histopathologic Data, G -Banding Karyotype, and CGH Copy Number Changes of the 37 Breast Carcinomas.
Case no. Histology* Gradey LNMz G-banding karyotypex,{ CGH copy number changes{
317 /92 Com 3,3,2 No 47–49,XX,add( 1 )( p31 ),der( 1 )add(1 )( p13 )
add( 1 )( q43 ), +der(1 )t( 1;11 )(q10;q10 )
add( 1 )( q42 ),3,4,7,der( 9 )t( 9;13 )( p13;q14 ),
del( 10 )(p12 ),11,13,13,14,15,
add( 19 )(p13 ), +4–6mar[ 32 ] / 91–98,idemx2[ 11 ]
rev ish enh( 1q21q22,3q24q28,6p,6q21q22,8q,
16q23qter )
363 /92 D 3,2,2 No 44–46,XX,+7[4 ] / 46,XX[ 47 ] rev ish dim(1p13p31,4,9p13pter,13q14qter )
386 /92 D nd No 46,XX,+1,der(1;16 )(q10;p10 )[ 3 ] / 46,XX[75 ] rev ish enh( 4q22qter,8p12qter,17q12q21,
20q12qter ),dim(3p12p14,5q15q33,6q13q25,
7q31qter,9p21pter,9q21,13q14qter,16q ),amp(8q )
394 /92 D 2,2,2 18 /18 48,XX,+5,+10[5 ] / 46,XX[45 ] rev ish enh( 3q21q24,3q27qter,5pterq13,5q34qter,
7q33qter,8p21qter,16p,17q24qter ),dim(Xpterq22,
11q23qter,13q14qter,16q,22q13 )
431 /92 Com 3,3,3 No 47,XX+7[ 8 ] / 46,XX[45 ] rev ish enh( 3p21p24,3q,4p16,8p11qter,11p14q14,
14q,16p11p13,16q23qter,17q21qter,19q,20q,
22q11q12 ),dim(1p31,4q23qter,5q11q22,6q16qter,
8p22pter,9pterq33,11q23qter,20p12pter,21q21 ),
amp(8q24,11q13 )
439 /92 Com 3,1,3 9 /11 66–80,XXX,+X,t( 1;14 )(p13;q12 )x2,del( 2 )
( q31 )x2,4,add(?6 )( q14 ), +7,+7,+8,9,+10,
add( 11 )(p14 ),add(12 )( p13 ),14,15,17,17,
17,18,19,+20,21,+4mar[ 5 ] / 46,XX[55 ]
rev ish enh( 10q21q22 )
501 /92 Crib 2,1,2 No 46,XX,del( 4 )( p12–3p15 )[ 4 ] / 46,XX[45 ] rev ish enh( 1q21q41 ),dim(6q16q22 ),amp(1q32 )
503 /92 D 3,1,3 4 /20 47–49,XX,+ i( 1 )(q10 ),der( 8 )del( 8 )( p21 )
ins( 8;10 )(q22;q22q24 ),der(8 )add(8 )(p11 )
ins( 8;10 )(q22;q22q24 ),+der(8 )add(8 )(p11 )
ins( 8;10 )(q22;q22q24 )x2,inv( 9 )( q12q34 ),10,
add( 11 )(q23 ),add(16 )(q22 )[ cp19 ] / 46,XX,t( 1;19 )
( p13;q13 )[ 4 ] / 46,XX[10 ]
rev ish enh(1q21qter,8q,10q21q22 ),
dim(8p22pter,10q25qter,16q )
509 /92 D 3,2,3 No 47–48,XX,+X[3 ] / 46,XX[19 ] rev ish enh( 8p12qter,16p,19p,20q13 ),
dim(6q12q21,13q21q22 )
512 /92 D 3,3,3 19 /19 66–67,XXX,del( 3 )(p13 ),+del( 3 )(p13 ),4,
+ 5,7,8,8,9,10,10,13,14,
add( 14 )?(p11 ),15,15, 16,17,17,17,18,
add( 20 )(q13 ), +add(20 )( q13 ),21,21,21,
inc[ 2 ] / 46,XX[55 ]
rev ish enh( 1q21q32,7p,8q,15q,17q11q21,17q25,
19,20q13,22q11q12 ),dim(1p21pter,1q42qter,
3p21pter,4q24q28, 4q34qter,7q21q31,8p12pter,
10q24qter,11q22qter,13q,18q12qter ),
amp(1q25q31,17q11q21 )
515 /92 Papil nd 1 /8 47,XX,+X[2 ] / 47,XX,+7[2 ] / 46,XX[46 ] rev ish enh( 1q,4p16,4p14q24,8p12qter,12q24,
16p,17q,19,20q ),dim(3p12p13,6p24pter,6q,
8p22pter,10q,11q14qter,13q,14q,16q,20p12pter ),
amp(8q21qter,20q12qter )
46 / 93 Crib 2,1,2 No 47,XX,+der( 1;16 )(q10;p10 )[ 2 ] / 47–48,XX,idem,
+der( 1;16 )(q10;p10 )x2,16[ cp5 ] / 46,XX[56 ]
rev ish enh(1q,16p )
80 / 93 Com 3,3,3 No 68–75,XX,X,add( 1 )( p22 ),+add(1 )(p22 ),
2,inv(2 )( p13q37 )x2,+3,del( 3 )(p12 )x2,
4,4,5,5,5,+6,add(6 )(q23 )x2,
add( 7 )( p21 ),+add(7 )(p21 ),der( 8 )t( 1;8 )( p22;q24 ),
der(8 )t( 3;8 )(p24;p22 ),10,11,12,dup(12 )
(q13q22 )x2,13,13,14,15, +add( 16 )( p12 ),
der( 16 )del( 16 )( p11 )add( 16 )(q23 ),17,18,19,
21,22,add( 22 )( q13 ), +8mar[ cp114 ] / 46,XX[11 ]
rev ish enh(1p36qter,2p11p13,3p21pter,
3p14qter,5q32qter,6pterq22,7,8p12qter,
9p21pter,10p14p15,11p15q12,12p13,12q14q21,
16p12,17p13,18pterq21,18q22qter,19p13q13.1,
21q21,22q11q12 ),dim(X,2p21pter,2q21q32,
2q35qter,4p15qter,5p14q23,6q24qter,8p23pter,
13q,14q21q22 ),amp(6p23pter )
92 / 93 D+DCIS 3,1,2 No 46,XX,del( 6 )( q21q23 )[ 2 ] / 46,XX[120 ] rev ish enh( 12q23qter )
100 /93 Com 3,3,3 No 46–47,XX,+7[4 ] / 46,XX, +1,der( 1;15 )(q10;q10 ),
ins( 1;? )( q11;? )[ 2 ] / 46,XX[64 ]
rev ish enh(Xq26qter,1q31q32,3p24pter,
8p12qter,12q14q22,17q21q25,20q11q13 ),
dim(Xp21pter,2p24pter,3p13p21,4q33qter,11p15,
11q21qter,13q12q21,14q,16q,20p12pter,21q21q22 )
113 /93 D 2,1,1 No 46,XX,der( 3 )inv( 3 )( p12p26 )del( 3 )( p13p21 )[ 4 ]/
46,XX,t( 7;9 )( p14;p24 )[ 2 ] / 46,XX[64 ]
rev ish enh( 1q21q42,16p ),dim(12p,13q21q31 )
136 /93 D 3,1,2 No 40–44,XX,add( 1 )( p34 ),3,der( 8 )hsr( 8 )( p?21 )
hsr( 8 )( q24 ),add(11 )(q21 ),13,16, +1–2mar
[ cp4 ] / 46,XX,+der( 1;16 )(q10;p10 ),10[3 ] / 46,
XX,t( 5;6 )( p14;q15 )[ 2 ] / 46,XX[85 ]
rev ish enh(1q22qter,6p24,9p13 ),dim(11q21qter,
13q13qter,16q,21q )
138 /93 D 3,2,3 No 46,XX,t( 1;20 )( p13;q13 )[ 14 ] / 48,XX,+3mar[ 2 ]/
46,XX[37 ]
None
206 Breast Cancer Clonality Teixeira et al.
Neoplasia . Vol. 3, No. 3, 2001
Case no. Histology* Gradey LNMz G-banding karyotypex,{ CGH copy number changes{
145 /93 D 2,2,3 5 /5 67–74,XXX,der( 1 )( 1qter!1p36::6qter!q15::? ),
i( 1 )( q10 ),add(2 )( q36 ),t( 3;6 )( p12;p22 ),4,
dic( 4;16 )(q31;q12 ),add(6 )( p23 ),del( 6 )( q15 ),
del( 7 )( p12 ),der( 7 )( 7pter!7q11::?::3p12!3pter ),
i( 7 )( p10 ),8,der( 8 )( 1pter!1p12::?::hsr::8p22!8qter ),
9,add( 9 )( p23 ),der( 10 )t( 3;10 )( p14;p13 ),
add( 11 )(q14 ),13,14,14,add( 14 )( p11 ),15,
del( 16 )(p11 ),del( 16 )(q12 ),17,add(17 )( q25 ),
add( 19 )(q13 ),add(20 )( q13 ),i( 21 )( q10 ),22,
+9–16mar[ 6 ] / 46,XX[71 ]
rev ish enh( 3q25qter,6p21,8q21q22,8q24,11p11p14,
12p13,17q24qter,18p,22q13 )
167 /93 Com 3,2,3 9 /14 37–42,XX,add( 1 )( p11 ),del( 2 )( q23 ),add(3 )( p12 ),
5,8,9,der( 10 )t( 3;10 )(p23;q22 ),der(11 )t( 8;11 )
(q12;p14 ),14,15,del( 17 )(p11p12 ),18,19,
21,add( 22 )( q12 ), +1–4mar[ cp13 ] / 74–80,idemx2,
add(1 )( p11 ), +add(1 )( p13 )x2,3,+der(3 )t( 3;8 )
(p12;q21 ),8,+ i( 8 )(q10 )[ cp15 ] / 149–150,
idemx4[2 ]
rev ish enh(8q21qter ),dim(11p13pter,17p13 )
199 /93 Com nd No 46,XX,del( 3 )(p14p22 )[ 10 ] / 46,X,t(X;3 )
( q22;p14 )[ 5 ] / 60–61,X,X,X,add( 1 )( p12 ),
2,2,der( 3 )add( 3 )( p14 )add( 3 )( q26 ),
4,5,5,6,7,8,8,
9,10,11,i( 12 )( p10 ),13,14,14,15,
dic( 16;? ) ( q23;? ),17,17,der( 20 )t( 5;20 )( q13;p13 ),
21,21, add( 22 )( p11 ), +3mar,inc[ 3 ]
rev ish enh( 1q24q31,7p,13q,14q12q21 ),
dim(3p13p22,6p22pter,8p12pter,
10q25qter,11p15,11q,14q24qter,
15q21qter,17p12pter,18p11.3 )
208 /93 Com 3,3,3 No 38–41,X,X,add( 1 )( p36 ),2,add( 3 )( q2?4 ),
del( 3 )(p12 ),add(4 )( p16 ),der( 4 )t( 3;4 ) (q2?4;q25 ),
add(7 )(q32 ),8,9,10,der( 10 )t( 4;10 )(q21;p15 ),
11,der( 12 )inv dup(12 )(q13q24 )add(12 )(q13 ),
13,14,der( 8;14 )( q10;q10 ),15,15,der( 17 )
t( 3;17 )(p13;p12 ),18, add( 19 )( p13 ),add(21 )(p11 ),
+2mar[ 10 ] / 38–41,idem,der( 12 )inv dup( 12 )
( q13q24 )add(12 )( q13 ), +der( 12 )inv dup( 12 )( q13q24 )
t( 1;12 )( q21;q13 )[ 6 ] / 38–41,idem,add(1 )( p36 ),
+del( 1 )( q41q43 ),5,+del( 5 )( q14q23 ),6,+add( 6 )
( q21 ),add(7 )( q32 ), +der(7 )add( 7 )( q32 )t( 7;13 )
( p15;q12 ),8,+del( 12 )( p11 ),der( 12 )inv dup( 12 )
( q13q24 )add(12 )( q13 ),13,14,+15,der( 17 )t( 3;17 )
( p13;p12 ), +der( 17 )t( 3;17 )( p13;p12 )add( 17 )( q25 ), +18,
+2mar[ 24 ] / 76–82,idemx2,add(1 )( p36 )x2,
+add(1 )( p12 )x2[ 8 ]
rev ish enh(Xp22,1q32,2q32q33,4q12q31,
6q22q24,7p14pter,8q,10p,11p14p15,12q13q22,
20q12qter ),dim(3p14p21,7q32qter,9p23pter,
10q21qter,11q23qter,13q,14q,15q26,
17p12pter,18p11.3,19q13 ),
amp(7p21p22,8q23,10p12p14 )
236 /93 D+Lob 1,1,1 4 /14 46,XX,i( 1 )( q10 )[ 2 ] / 46,XX[158 ] rev ish enh( 16p13 ),dim(16q,22q13 )
244 /93 Muc nd No 46,XX,t( 3;19 )( p21;q13 ),t( 11;20 )(q14;q13 )[ 7 ] / 46,
X,der(X )t(X;3 )( q22;p21 ),del( 2 )( q14 ),add(3 )( p21 ),
del( 4 )( p14p15 ),del( 4 )( q21 ),add( 5 )( p15 ),del( 5 )( q23 ),
del( 7 )( q22q32 ),add(10 )( p15 ),add( 12 )( p13 ),
der( 16 )t( 5;16 )( q31;p13 )add( 16 )(q23 )[ 5 ] / 46,XX,
t( 1;11 )( p36;p14 ),4,der( 6 )t( 6;7 )( q13;q22 ),add( 7 )
( q22 ),der( 18 )t( 4;18 )( q13;q22 ), + r[ 3 ] / 47,XX,t( 7;19 )
( p15;q13 )[ 2 ] / 46–47,XX,t( 16;17 )( p11;q21 )[ 2 ] /
46,XX[41 ]
None
248 /93 Com 3,3,2 No 56–59,X,add(1 )(p35 ),add(1 )( p12 ),t( 1;6 )( p34;p24 ),
add(3 )(p24 ),dic( 7;7 )(q22;q22 ),add(10 )(q22 ),
add( 11 )(q22 ),add(16 )( p13 ), + r, +3mar,inc[ 14 ] / 46,XX,
t( 1;16 )( p34;q23 )[ 2 ] / 46,XX[170 ]
rev ish enh( 1p31p34,1p13p21,1q21q31,
2p24pter,2p12p13,2q22q32,3q13qter,5p13p15,
6p21qter,7p15qter,8q21qter,10p,10q11q21,
11q13q22,12p,13q12q31,16p13,20q ),
dim(Xp11pter,1p36,3p24pter,4p11p15,
4q21qter,5q11q34,
8p21pter,10q23q25,11p11pter,15q22qter,
18q22qter ),
amp(7p11p14,7q11q21,8q24 )
335 /93 D 3,3,2 7 /18 62–68,XX,X,del( 1 )( p22 ),der( 1 )( 1qter!cen!1p31::
1p36!1p31::? ),2,4,5,add(6 )( q23 ),
+del( 7 )(q32 ),8,8,9,9,+add(12 )(p13 ),
13,15,15,16,add( 16 )(q23 ),del( 16 )( q22 ),
17,18,21,22,inc[ 16 ]
rev ish enh( 1p21qter,5p12p15,7pterq21,
8q21qter,12,13q,17q,20 )
361 /93 Com 3,2,2 4 /24 59–63,XX,X,der( 1;16 )( q10;p10 )x2,i( 1 )( q10 ),
add( 13 )(p11 ),der( 19 )t( 7;19 )(q11;q13 ), +der( ? )
t( ?;5 )( ?;q11 ),inc[ 2 ]
rev ish enh(Xq27qter,1q31q32,
2q23q32,4q32q34,6q21q22,6q23q24,
8q11q24.1,11q13q14,12q14q22,14q12q22,
20q11q13 ),
dim(6p21.3,9p12,17p11pter,17q25,19p13 )
Table 1. (continued).
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number of changes per case detected by G-banding and
CGH was, respectively, 9.6 and 10.5, cases with 0 to 10 and
more than 10 genetic changes detected by either technique
were tabulated for statistical analysis (Table 2).
Case no. Histology* Gradey LNMz G-banding karyotypex,{ CGH copy number changes{
392 /93 Com 3,1,2 No 79–?84,del( 7 )( q21 ),inc[ 2 ] / 46,XX[67 ] rev ish enh( 1q24q41,3p24pter,
5p13q34,6q16q22,8p11q24.1,9q13q21,
9q31q34,18q12q21 ),dim(2q36qter,13q,17p )
467 /93 D 3,1,2 No 47,XX,+1,der(1;16 )(q10;p10 ),r(?11 ), + 20[ cp19 ]
/ 46,XX[21 ]
rev ish enh(1q,11p14p15,11q12q14 ),
dim(11q22qter,16q )
495 /93 DCIS nd No 46,XX,t( 8;19 )( q22;q13 )[ 2 ] / 46,XX[12 ] rev ish enh( 1q23q32,1q43qter )
507 /93 D 2,3,3 No 46,XX,add(1 )( q21 )[ 2 ] rev ish enh( 1q24qter,3p24pter,3q25qter,
6q15q22,7q31q32,8q22qter,9q31q33,
10p13pter,11p11p15,17q23,18q12 ),
dim(1p36,5q34qter,10q25qter,16pterq21,17p12pter )
535 /93 Lob nd No 62–80,XXX,+7,+10,+12,+14, +15,+mar[ cp5 ]
/ 46,XX[110 ]
rev ish enh( 1q31,5q23q31,12q15q21 )
557 /93 D 3,3,3 No 46,XX,+1,der( 1;16 )(q10;p10 )[ 2 ] / 46,XX[168 ] rev ish enh(Xq25q27,1q31q32,2p24pter,
4q13q21,5p,6q15q16,6q22,8q22qter,9p13pter,
10p13pter,10q22,12p11p12,20q11qter ),
dim(8p21pter,14q24qter,15q26 )
566 /93 D 2,2,1 No 46,XX,+1,der( 1;10 )(q10;p10 )[ 2 ] / 46,XX[81 ] rev ish enh( 1p13p31,1q23q32,3p22p24,
3p12p14,3q24q26,4q12q33,5p13,8p12qter,
12p11p12,12q21,16p11pter ),dim(6p21pter,
16q22qter,17p11p12 ),amp(8q )
574 /93 D 2,1,2 No 46–47,XX,t( 3;6 )( q21;q25 )[ 2 ] / 46,XX[78 ] rev ish enh( 1q24q32 ),dim(6p12p21.1,6q23qter,
16q,17pterq21 )
2 / 94 D 3,2,3 No 74–80,XX,i( 1 )( q10 )x2, + 3r,inc[ 2 ] / 46,XX[47 ] rev ish enh(1q,5p,7p21p22,10q21q23,15q21qter,
16p13,17q21qter ),dim(8p,10q25qter,11q22qter,
13q,16q22qter,17p12pter,18,22q ),
amp(1q32qter,17q22q24 )
7 / 94 Papil nd No 73–76,XXX,del( 1 )( q21 ),i( 1 )( ?::q44!q10::q10!
q44::? ),del( 7 )(q21 ),add(16 )(q22 ),del( 16 )( q13 ),
inc[ 6 ] / 46,XX[53 ]
rev ish enh( 1p32qter,2p16pter,3q,5p,6p22q16,
6q22q25,7p14pter,7q21,8q13qter,10p,11pterq14,
12q22,13q13q32,18 ),dim(1p34pter,2q11q35,
3p12pter,5q13q14,7q31qter,10q21q22,11q23qter,
12q14q15,14q,15q11q25,17pterq12,17q24qter,
20q ),amp(7p21 )
*Com, comedocarcinoma; Crib, cribriform carcinoma; D, ductal carcinoma; DCIS, ductal carcinoma in situ; D+DCIS, ductal carcinoma with extensive in situ
component; Lob, lobular carcinoma; Muc, mucinous carcinoma; Papil, papillary carcinoma.
yHistologic grade as subdivided in three components, i.e., tubule formation, mitotic activity, and nuclear pleomorphism; nd, not determined (histologic grading is
done routinely only for ductal carcinoma not otherwise specified ).
zLymph node metastasis.
xThe G-banding karyotypes of cases 386 /92, 503 / 92, 46 /93, 136 / 93, 145 /93, 361 / 93, and 467 /93 were published in Tsarouha et al. [ 10 ].
{In bold are shown the G-banding and CGH findings that are likely to belong to the same clonal cell populations in the individual cases.
Table 1. (continued).
Table 2. Relationship Between Histopathologic Grade and the Number of Chromosome Abnormalities (G -banding ) and Copy Number Changes (CGH).
Grade* G -bandingy CGHz G-banding /CGHx
Tubular formation 0–10 >10 P= .200 0–10 >10 P= .690 0–10 >10 P= .230
1–2 8 1 6 3 5 4
3 12 9 11 10 6 15
Mitotic index 0–10 >10 P= .045{ 0–10 >10 P= .007{ 0–10 >10 P= .004{
1–2 16 4 15 5 11 9
3 4 6 2 8 0 10
Nuclear pleomorphism 0–10 >10 P= .440 0–10 >10 P= .270 0–10 >10 P= .140
1–2 12 4 11 5 8 8
3 8 6 6 8 3 11
Combined grade 0–10 >10 P= .120 0–10 >10 P= .063 0–10 >10 P= .026{
I – II 13 3 12 4 9 7
III 7 7 5 9 2 12
*The combined grade is arrived at by adding the three individual scores for tubular formation, mitotic index, and nuclear pleomorphism (each with a score of 1 to 3 ).
Grade I: 3 to 5; grade II: 6 or 7; grade III: 8 or 9. The individual scores 1 and 2 and the grades I and II were grouped together for the purpose of statistical analysis.
yThe number of cytogenetic abnormalities in each case was arrived at by counting the abnormalities described in the karyotype. Multiple copies of structural or
numerical abnormalities were counted only once; in derivative chromosomes, each structural change was counted; each individual marker was counted once.
zThe score was arrived at by adding the number of copy number gains and losses indicated in Table 1; amplifications were not counted because the regions
involved are always part of usually wider regions registered as copy number gains.
xThe highest number of changes detected by G-banding or CGH was used for a combined score.
{Statistically significant finding.
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Statistical Analysis
Fisher’s exact test was used to determine the relation-
ship between the number of genetic changes and grade
( including each of its components individually ) and
between genetic complexity and histological type. The
correlation coefficient ( r ) was determined to study the
correlation between the number of changes detected with
G-banding and CGH, as well as the correlation between
the copy number gains and losses detected by CGH.
Two- tailed P values .05 were considered statistically
significant.
Results
The G-banding analysis revealed 24 cases with a single
karyotypically abnormal clone and 13 cases (35%) with
multiple clones. Nine of the 13 cases showed polyclonality in
the form of two to five cytogenetically unrelated clones per
case. Twelve cases presented a neartriploid clone and three
other cases with stemlines in the neardiploid range showed
additional, related clones that were neartriploid, neartetra-
ploid, and/or nearhexaploid. The remaining 22 cases had
only neardiploid clones with variable degrees of karyotypic
complexity. The most common structural chromosome
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Figure 1. Graphic comparison of the genomic gains (A) and losses (B) detected by G-banding (green) and CGH (red) from 1p36 to Xq28 (all cases pooled). For
every case, the presence or absence of imbalance in every chromosome band was computed in a spreadsheet. The total number of imbalances detected by each
technique in every band was then used to prepare the graphic comparison. Imbalances in some areas of the genome are equally often detected by both techniques
(e.g., gain of 1q and losses of 3p, 6q, 8p, 11q, and 16q). However, CGH seems to detect more often gains of 3q, 6q, 8q, 11, 16p, 17q and 20q, whereas G-banding
more often detects losses of 1p, 2q, 4, 9q, 15q, and 17q. These differences might be explained by the preferential detection of disparate clones by each technique or
by the frequent presence of the said chromosomal segments in marker chromosomes or in chromosomes that by G-banding are seen to have addition of unknown
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abnormalities were der(1;16)(q10;p10) (detected in six
cases, in three as the sole change and in three as part of
complex karyotypes) and i(1)(q10) ( five cases, in one of
them as the sole change), whereas +7 was the most
frequent numerical change (six cases, in four of them as the
sole change). A detailed description of all clonal chromo-
some abnormalities is presented in Table 1.
All but two cases presented copy number changes by
CGH (Table 1). The number of imbalances per case ranged
from 0 to 30 with an average of 10.5 per case. The number of
copy number gains varied from to 0 to 20 (average: 6.2) and
the losses from 0 to 13 (average: 4.4); gains and losses
were significantly correlated with one another ( r=0.63;
P<.001). The chromosome arms from which material was
most frequently gained were 1q ( the band most commonly
gained was 1q31 with 62.2%), 8q (56.8% at 8q22 and 8q24),
20q (29.7% at 20q13), and 16p (27.0% at 16p13), whereas
the ones most often displaying losses were 13q (35.1% at
13q21), 11q (29.7% at 11q23q25), 16q (29.7% at
16q22q24), 8p (24.3% at 8p23), and 17p (24.3% at
17p12p13; Figure 1 ). Eleven tumors showed amplifications
(here defined as ratios above 2.0; Table 1) in one to three
discrete chromosomal regions, most frequently at 8q (six
cases), 1q ( three cases), 7p ( three cases), and 17q ( two
cases).
The comparison between genetic complexity and the
individual components of the histopathologic grade
revealed a statistically significant association between high
mitotic index and the presence of many genetic changes
detected both by G-banding and CGH (P=.045 and
P=.007, respectively; Table 2). No such association was
discernible with the other two components or with the
overall grade when the findings of each technique were
considered in isolation. However, when the findings of both
techniques were combined so that the one yielding the
highest value was used, a statistically significant associa-
tion emerged between grade III and genetically complex
tumors ( i.e., >10 genetic changes; P=.026). Genetic
complexity varied also with histologic tumor type. The
carcinomas with a cribriform, lobular or DCIS histology
presented relatively few genetic changes by G-banding/
CGH (average 2.7 changes), whereas the two papillary
carcinomas and the single mucinous carcinoma presented
19, 27, and 22 genetic changes, respectively (Table 1).
Differences were also seen in the two more common
groups of tumors: All 11 comedocarcinomas (range: 11 to
36; average: 23.4), but only 10 of 17 ductal carcinomas
NOS (range: 4 to 44; average: 12.9) had more than 10
genetic changes per case by G-banding/CGH (P=.023).
Amplifications were more often seen in tumors with many
genetic changes (P=.057). No association was detected
between genetic complexity and the presence of lymph
node metastases. The correlation between the number of
changes detected by G-banding and CGH was not
statistically significant ( r=0.20; P=.212).
Discussion
The overall picture of the karyotypic findings in the 37 breast
carcinomas we present does not differ significantly from that
of a larger, unselected series previously analyzed with the
same technique [1], neither with regard to which clonal
chromosome aberrations were the most common nor with
regard to the clonal composition of the tumors. Similarly, in
spite of the fact that cases with an abnormal G-banding
karyotype had been selected for, the genomic imbalances
detected by CGH in our study were similar to those found in a
consecutive series of 55 breast carcinomas [12]. Therefore,
the findings we arrived at by combined G-banding and CGH
analysis of the chosen set of 37 tumors seem to be
representative of breast carcinomas in general.
To be able to compare the G-banding and CGH findings,
the chromosomal imbalances in each case were deduced
from the karyotypic data (Figure 1 ). Similar imbalances
detected by both techniques were discernible in 14 of the 37
breast carcinomas, making it overwhelmingly likely that the
same clonal cell populations were being looked at in these
cases. In the two cases in which no imbalance was detected
by CGH, the chromosome banding analysis had revealed
only balanced rearrangements in the mainline, and so the
findings here, too, may be considered to be in agreement.
Some of the matching cases (e.g., 512/92, 80/93, and 335/
93; Table 1 and Figure 2 ) presented neartriploid clones with
numerous chromosomal alterations, whereas others had
neardiploid clones with many (e.g., cases 503/92, 136/93,
167/93, and 208/93; Figures 3 and 4 ) or only a few changes
Figure 2. G-banding karyogram (A) and CGH profile (B) showing the same clonal cell population in a breast carcinoma (case 80/93) with complex genomic changes.
See Table 1 for a full description of the acquired clonal aberrations. The changes present in this metaphase that are not indicated in the karyotype are nonclonal.
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(e.g., case 46/93 presented only rev ish enh(1q,16p) due to
a supernumerary der(1q;16p)). Because the imbalances
corresponding to the banding karyotypes were detected by
CGH, both the clones with simple chromosomal abnormal-
ities and the more complex ones must have made up a
significant fraction of the test sample, even when the G-
banding analysis after culturing revealed only a few
representative metaphases (e.g., cases 512/92, 46/93,
136/93, and 2/94). The results therefore provide further
evidence that breast carcinomas are clonally heterogeneous
Figure 3. Partial karyograms and CGH profiles showing the increased
understanding of the acquired genetic changes obtained by the combined
analysis. (A) The genomic imbalances detected by CGH (rev ish enh(1q,16p))
in case 46/93 are due to one (left) and three (right) supernumerary der(1q;16p)
present in two related subclones. The loss of one chromosome16occurredonly
in one subclone, which explains why the ratio profile did not reach 0.75 at 16q.
(B) The presence of a der(1q;16p) instead of a normal chromosome16 explains
the gain of 1q and loss of 16q seen by CGH in case 467/93. The imbalances
detected by CGH in chromosome 11 showed that the ring chromosome
contained multiple copies of 11p14p15 and 11q12q14 but no 11q22qter
material. The ring was unstable and was larger in some cells (right). (C)
Chromosome banding analysis showed that the rev ish enh(8q,10q21q22) and
rev ish dim(8p) detected by CGH in case 503/92 derived from the presence of
multiple copies of an abnormal chromosome 8 having an insertion of a segment
of 10q in its longarmaswell as loss of 8pmaterial. In this case, thegain of 1qand
loss of 16q are independent events, because the gain of 1q resulted from an
i(1q) and not from a der(1q;16p). The inv(9) is not detectable by CGH.
Figure 4. Imbalances brought about by two cytogenetically unrelated clones
(A and B) were simultaneously detected by CGH (C) in case 136/93, indicating
that both clones were large in vivo and, by inference, were part of the tumor
parenchyma. See Table 1 for a full description of the acquired aberrations. The
changes not indicated in the karyotype are nonclonal.
Neoplasia . Vol. 3, No. 3, 2001
Breast Cancer Clonality Teixeira et al. 211
and that cytogenetic complexity is an insufficient criterion to
judge the pathogenetic relevance of these clones by.
In the remaining 21 tumors, the comparison of the G-
banding and CGH findings revealed no clear concordance.
This has two main explanations: First, the extreme
complexity of the karyotypic abnormalities in some cases,
with numerous chromosomes with additional material of
unknown origin and markers (many of these corresponding
to amplifications detected by CGH; Figure 5 ), made detailed
and complete description of the chromosomal anatomy
based on G-banding appearance impossible (e.g., cases
145/93, 248/93, and 392/93). A reliable assessment of
karyotypic imbalances based on chromosome banding
analysis alone is difficult in such instances, and so it is
nevertheless likely that both techniques did detect the same
clones also in these cases. Second, the chromosomal
changes detected by the G-banding and CGH analyses
might be present in different tumor cell subpopulations.
Because CGH requires that one copy loss or gain be
present in at least 50% (or more in a hyperdiploid tumor) of
the cells to be scored using thresholds of 0.75 and 1.25,
respectively, anything but major clones will remain unde-
tected. This probably explains why der(1q;16p) was
detected as the single chromosomal abnormality by both
techniques in case 46/93, but was not seen by CGH in case
557/93. However, although the cytological nature of G-
banding analysis enables it to pick up also small cell
subpopulations and clones presenting only balanced chro-
mosome rearrangements (e.g., cases 495/93 and 574/93),
selection bias may occur during culturing if some clones
thrive better than others in vitro. This explains the CGH
copy number changes that the G-banding karyotypes of
some cases (e.g., 394/92, 431/92, and 507/93) cannot
account for. The study by Persson et al. [13] permitted a
similar conclusion. Thus, both G-banding and CGH
analyses underestimate the cytogenetic heterogeneity of
breast carcinomas and, in principle, tumor cell populations
in general, although their combined use goes some way
toward providing a more realistic picture. This conclusion is
also supported by the lack of a statistically significant
correlation between tumor grade and the number of genetic
changes detected by either G-banding or CGH, whereas
grade III carcinomas were significantly correlated with high
genetic complexity as ascertained by the combined G-
banding/CGH approach (Table 2).
Chromosome banding analysis revealed cytogenetically
unrelated clones in eight cases (cases 503/92, 515/92,
100/93, 113/93, 136/93, 199/93, 244/93, and 248/93).
Although CGH reveals the genomic imbalances of an
idealized, average cell, the copy number changes detected
in two of these cases (503/92 and 199/93) could be
ascribed to only one clone, in all likelihood the quantitatively
dominant one in vivo. This is in keeping with the commonly
held view that, at any one time, the selection pressure will
work in favor of only one neoplastic cell subpopulation [14].
The apparently disparate findings seen in other cases are
explained by the methodological limitations indicated above.
Interestingly, however, the copy number changes detected
by CGH in case 136/93 corresponded to the genomic
imbalances seen in two of the three cytogenetically
unrelated clones revealed by G-banding ( the third clone
carried a balanced translocation only, and could therefore
not be detected by CGH; Figure 4 ). The rev ish
enh(1q22qter) is attributable to the der(1;16)(q10;p10) of
one clone, the rev ish dim(11q21qter,13q13qter) is attrib-
utable to the add(11)(q21) and monosomy 13 of the other
clone with more complex chromosomal abnormalities,
whereas the ish rev dim(16q) is explained by the average
of the two aforementioned clones, because one presents
monosomy 16 and the other gain of 16p due to the
presence of a der(1q;16p) in addition to two normal copies
of chromosomes 1 and 16. The additional, apparently
nonmatching imbalances are accounted for by the markers,
the homogeneously staining regions, and the additional
material of unknown origin detected by chromosome
banding analysis. In this case, therefore, both clones must
have made up a considerable fraction of the tumor providing
strong, albeit indirect, evidence that the cytogenetically
unrelated clones often detected in breast carcinomas are
part of the neoplastic parenchyma. Polyclonal tumorigene-
sis in some breast carcinomas is the simplest explanation
for these findings.
Because the picture of genomic alterations revealed by
the two techniques overlapped only partly, we were able to
combine them to extract more information than is possible
with each of them alone. CGH, besides sometimes revealing
genomic imbalances that belonged to cell populations not
Figure 5. Amplifications (ratio >2.0) were mostly seen in cases with complex
abnormalities detected by either G-banding or CGH. Top row: amp(1q25q31),
amp(6p23p25), amp(7p21p22), and amp(7p11p14,7q11q21). Middle row:
amp(8q23), amp(8q24), amp(8q), and amp(10p12p14). Bottom row:
amp(11q13), amp(17q11q21), amp(17q22q24), and amp(20q12q13).
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picked up by the cytogenetic analysis, gave a more reliable
overall picture of the copy number gains and losses in cases
where the G-banding karyotypes had many markers and
chromosomes with additional material of unknown origin.
Furthermore, when both techniques detected relatively few
changes that could more easily be seen to be the same, the
CGH findings helped determine the origin of chromosomal
segments and to refine breakpoints. For instance, in case
503/92 the CGH analysis helped us to understand that the
segment of 10q material inserted in 8q was 10q21q22
instead of the more distal 10q22q24, whereas in case 467/
93 CGH identified the segments of chromosome 11 that were
lost (11q22qter ) and gained (11p14p15 and 11q12q14) in
the ring chromosome (Figure 3 ). No gain of chromosome 20
was found by CGH in spite of the +20 detected by G-
banding in case 467/93, however, which was compatible
with the finding of this trisomy by the latter in only four of the
19 cells with r(11).
However, besides sometimes revealing cell populations
with balanced chromosome aberrations or unbalanced
changes that nevertheless remained undetected by CGH,
chromosome banding analysis was essential to understand
how the genomic imbalances arose in the many cases in
which both techniques detected the same clonal abnormal-
ities. For instance, in case 46/93 the G-banding data tell us
that the rev ish enh(1q,16p) arose through the presence in
the stemline of a der(1;16)(q10;p10) in addition to two
normal chromosomes 1 and 16, whereas a subclone had
acquired two additional der(1q;16p). Simple though it was,
the nature of this chromosome abnormality could not be
deduced from the CGH data alone, especially against the
background that the der(1q;16p) in most breast carcinomas
is seen instead of a normal chromosome 16, resulting in gain
of 1q but loss of 16q. Loss of one normal chromosome 16 did
indeed occur in a subclone, but the ratio profile at 16q did not
reach the 0.75 level as this chromosomal arm was lost only in
a subpopulation of neoplastic cells. Even more strikingly, in
case 503/92 the chromosome banding analysis clearly
showed that the rev ish enh(8q,10q21q22) and rev ish
dim(8p) detected by CGH were not independent events, but
instead derived from the presence of multiple copies of an
abnormal chromosome 8 having an insertion of a segment of
10q in its long arm as well as loss of 8p material (Figure 3 ).
Knowledge of the chromosomal organization of karyotypic
changes, not only of the resulting imbalances, is important in
order to study possible position effects, including the
occurrence of fusion genes, resulting from them.
A nonrandom association between genetic complexity
and histologic tumor type was apparent in the series we
present. With regard to the cases with special histology, all
carcinomas with a cribriform, lobular or DCIS histology
presented relatively few genetic changes by the combined
G-banding/CGH analysis, whereas the two papillary carci-
nomas and the single mucinous carcinoma presented
numerous genetic changes (Table 1). Furthermore, come-
docarcinomas are more often genetically complex than
ductal carcinomas NOS. That different histological subtypes
of breast carcinoma may be associated with different
degrees of genetic complexity has also been found in other
studies, both with chromosome banding analysis [15–17]
and CGH [12,18–20]. Further analysis of larger series is
nevertheless necessary to test whether genetic subtyping of
breast carcinomas really leads to new information reliable
enough to have an impact on how these patients should be
treated.
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